GSK Acquires Global Rights to Chinese Cancer Drug in $750 Million Deal
British pharmaceutical giant GSK buys full global rights to a multiple myeloma treatment from Chengdu-based Chimagen Biosciences.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 2 articles since 15 Sept 2026. STAT published first, on 15 September at 13:29 UTC; South China Morning Post followed 12h 30m later. The most recent article, from South China Morning Post, appeared on 16 September at 02:00 UTC.
Outlets reporting it: STAT, South China Morning Post.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- GSK
- Chimagen Biosciences